Last reviewed · How we verify
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 in combination with cevostamab in participants with relapsed/refractory multiple myeloma (R/R MM) who have received a minimum of three prior treatments, including at least one immunomodulatory drug (IMiD), one proteasome inhibitor (PI), and one anti-CD38 monoclonal antibody.
Details
| Lead sponsor | Genentech, Inc. |
|---|---|
| Phase | PHASE1 |
| Status | ACTIVE_NOT_RECRUITING |
| Enrolment | 90 |
| Start date | Tue Mar 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed Nov 18 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Multiple Myeloma
Interventions
- Cevostamab
- XmAb24306
- Tocilizumab
Countries
Israel, Greece, South Korea, Norway, Spain, Denmark, Australia